B

헬릭스미스

084990KOSDAQ자연과학 및 공학 연구개발업

60.8 / 100

Reference Date: 2026-07-24

Financial Score25.5 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 18.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Helixms is a biotech company established in 1996, specializing in CDMO, clinical CRO, analytical CRO, and H&B (health and beauty) businesses. It operates a state-of-the-art GMP facility compliant with FDA and Korean regulatory standards, and leverages natural-derived material technologies to develop pharmaceuticals and B2B products. The company also focuses on cell and gene therapy production, with extensive experience in global clinical trials and regulatory compliance.

Number of Employees

44people

Average Salary

54.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 43.644.0Point
PBR
1.12Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE
-0.33Industry Average -32.093.5Point

Well below industry avg

Debt Ratio
0.62Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼14.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲47.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -15.2% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 3,450Won52-week high 9,47052-week low 3,010
1-month return0.0Point

1m -18.92% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0